Introduction
============

In women, breast cancer is considered to be the main cause of women's deaths worldwide (Bray et al., 2018). There were more than two million newly diagnosed as breast cancer in women worldwide in 2018 (Bray et al., 2018; Jenkins et al. 2018).There will be an estimated 18.1 million new cancer cases and 9.6 million cancer deaths in 2018. In Vietnam, the incidence of breast cancer has been increasing steadily, from 13.8 per 100,000 women in 2000 to 29.9 per 100,000 women in 2010 and tends to increase year by year to 12,533 cases (Dieu et al., 2012; Jenkins Chris et al., 2019).

The proto-oncogene HER2/neu (C-erbB-2) has been localized to chromosome 17q21.1 and encodes a transmembrane tyrosine kinase growth factor receptor (Muleris et al., 1997). HER2 (human epidermal growth factor receptor 2) is a member of the epidermal growth factor receptor family, encodes a 185 kDa transmembrane glycoprotein with tyrosine kinase activity (Saini et al., 2011). Most studies on *HER2*-found this gene was involved in inducing mammary carcinogenesis. *HER2/neu* gene amplification has been associated with the development of breast cancer (Piechocki et al., 2007).

Several HER2-targeted therapeutic strategies have potential to adopt the *HER2* overexpression tumor cells: monoclonal antibodies downregulate*HER2*expression by binding to the extracellular domain (such as trastuzumab and pertuzumab); antibody-drug conjugates (such as trastuzumab emtansine, called T-DM1); and tyrosine kinase inhibitors (such as lapatinib and neratinib), which compete for ATP-binding to block HER2 signaling (Di Modica et al., 2017). Metastatic HER2-positive breast cancer patients receiving HER2-targeted therapy typically experience better outcomes and improved prognosis than those with HER2-negative disease (Wilson et al., 2018). Accurate evaluation of HER2 status is essential for the management of patients eligible for HER2-targeting therapy. Therefore, overexpression of HER2 protein or gene amplification has been recognized as a prognostic factor of breast cancer.

Gene amplification and protein overexpression of *HER2* are found in approximately 15%- 20% of BC (Varga et al., 2013). IHC method of HER2 protein detection is advantageous, convenient, inexpensive, and only requires conventional microscopy. However, the results may be influenced by the time and the fixation protocol, the antibody clone, and most importantly it is difficult to apply the score sheet to have accurate conclusions. Therefore, for an ambiguous result obtained by immunohistochemical staining, the exact state of *HER2* gene amplification should be assessed by performing fluorescent in situ hybridization (FISH) or dual chromogenic in-situ hybridization (DISH) because of its high accuracy and reliability, although expensive (Ellis et al., 2005).

The correlation between *HER2* gene expression and breast cancer is not clear. According to most studies, it is thought that *HER2* overexpression is a poor prognostic factor (Allred et al., 1992). The breast cancer parameters such as lymph node metastases, tumor grade, cell proliferation were reported that associated with the gene expression of *HER2* (Aman N. A. et al., 2019a; Pengfei et al. 2019). In the initial reports, HER2/neu amplification was an important predictor of early relapse and death in breast cancer. *HER2* gene amplification has a significant predictor of both disease-free survival and time to relapse in breast cancer patients (Iqbal and Iqbal, 2014; Parkes et al., 2010a). However, several authors demonstrated that amplification of *HER2* gene relate to ER, PR status but not correlate with age, tumor size and lymph node (Shokouh et al., 2015).

HER2 served as a poor prognostic indicatory but good predictor for response to anti HER2 therapy. Therefore, it is really meaningful to investigate correlation between HER2 expression and other clinicoopathologic parameters in Vietnamese women.

Materials and Methods
=====================

*Patients and specimens*

The cross-sectional study was conducted on patients with primary invasive breast carcinomas in Hue University Hospital and Hue Center Hospital, Hue city, Vietnam from June 2016 to August 2018. The specimens were obtained from surgical resection of patients diagnosed with primary breast cancer, which have not been treated with pre-operative chemotherapy in the past yet. Patient's information were extracted using a checklist including age, menopausal status, site, histological type, grade, stage, lymph node involvement and status of ER, PR, HER2, Ki-67. The status of ER, PR, HER2 and Ki-67 were determined by IHC upon the formalin fixed paraffin-embedded blocks of breast carcinoma patients.

All specimens were processed for histopathologic examination according to WHO Classification (Frank et al., 2013) by using hematoxylin and eosin staining and graded with the criteria of Elston and Ellis (2002).

*Immunohistochemistry staining*

The immunohistochemical staining was conducted on 3 μm thicknesses of breast tissue sections on the automated VENTANA BenchMark ULTRA platform (Ventana Medical Systems Inc., Tucson, AZ, USA) using antibodies: anti--Estrogen receptors (SP1), anti-Progesterone Receptor (1E2), anti-HER2/neu (4B5), anti-Ki-67 (30-9). IHC results were evaluated under light microscope. The Estrogen receptor (ER), Progesterone receptor (PR) staining results were scored as positive when greater than or equal to 1% of tumor cell nuclei were stained. Immunohistochemical analysis of the tumor proliferation index marker Ki-67 was performed using a cut-off point of 14%. HER2 protein expression were assessed based on intensity cell membrane immunostaining and the percentage of membrane positive cells. HER2 expression were classified from 0 to 3+; IHC staining 0, with absence or \< 10% of invasive tumor cells with faint staining; IHC staining 1+, with \> 10% of invasive tumor with faint incomplete membrane staining; IHC 2+, with \> 10% of invasive tumor cells with incomplete or week membrane staining or ≤ 10% of invasive tumor cells with intense membrane staining; IHC 3+, with \>10 % of invasive tumor cells with uniform intense membrane staining.

*Dual color in situ hybridization*

*HER2* gene amplification was defined by dual color in situ hybridization using the inform HER2 dual in situ hybridization DNA probed cocktail assay on the automated VENTANA BenchMark ULTRA platform (Ventana Medical Systems Inc., Tucson, AZ, USA). DNA Probe Cocktail assay is designed to determine *HER2*gene status by detecting HER2 copies via silver in situ hybridization (SISH) (black) and chromosome 17 copies via chromogenic Red in situ hybridization (Red ISH) on a single slide. Pathologists scored the DISH studies, counting at least 20 tumor cells. The criteria consist of a combination of the HER2/CEP17 ratio and the average number of HER2 signals per cell. The *HER2* gene amplification was scored as "amplified" if the case had a HER2/CEP17 signal count ratio of 2.0 or if the HER2/CEP17 signal count ratio was \<2.0 but the average number of HER2 signals per cell were 6.0. A score of "equivocal" was given if the case had a HER2/CEP17 signal count ratio of \<2.0 and the average number of HER2 signals per cell were ≥ 4.0 and \<6.0. A score of "not amplified" was given if the case had a HER2/CEP17 signal count ratio of \<2.0 and the average number of HER2 signals were \<4.0 (Nishimura et al., 2016a; Nishimura et al., 2016b).

*Statistical analysis*

The data was analyzed using R and Statistical Package for Social Sciences (SPSS, Ver 17). Chi square tested was used to test the relationships between the clinicopathological factors and *HER2*expression. A p-value of less than 0.05 was considered statistically significant.

Results
=======

*Patient and tumour characteristics of breast cancer patients*

The clinicopathologic characteristics of breast cancer patients are presented in [Table 1](#T1){ref-type="table"} and Supplementary [Figure 1](#F1){ref-type="fig"}. The majority of patients were older than 40 years of age (54.70 ± 12.66) and location of breast tumor was different, in which the upper outer quadrant was the most frequent site (54.69%). The predominant histological type was invasive carcinoma of no special type (NST) with 181 cases (77.35%). The significant difference was found when subtypes were compared to histological grade. The highest percentage of patients with Grade II was detected (59.36%). Median tumor diameter was 3.37 ± 1.83 cm (27.16% cases ≤ 2cm and 72.84% case \> 2cm). Lymph node metastases were available in 57.86% cases (68 cases with 1-3 lymph nodes metastases and 46 cases have over 4 lymph nodes metastases) and 42.13% of cases with no lymph nodes available (83 cases). There were significant differences in the distribution of stage of the breast tumors. In Supplementary [Figure 1](#F1){ref-type="fig"}, the breast cancer staging was 11.22% for stage I, 59.18% for stage II, 29.60% for stage III. The Nottingham prognostic index (NPI) is an established prognostication tool for the management of breast cancers (Fong et al., 2015). The majority of patients were classified as moderate Nottingham prognostic index (107 patients, 54.9%).

*Molecular characteristics of patients with breast cancer*

The molecular characteristics of breast cancer patients are summarized in [Table 2](#T2){ref-type="table"} and Supplementary [Figure 2](#F2){ref-type="fig"}. *HER2* gene amplification status was estimated by DISH ([Figure 1](#F1){ref-type="fig"}). In 100 cases DISH analyzed, 31 cases showed the result of the amplification of *HER2* gene in breast cancer. Overexpression of HER2 protein of breast cancer tissues was accessed by IHC ([Figure 1](#F1){ref-type="fig"}). In 237 cases, 68 cases (28.69%) were scored as HER2 IHC positive (2+, 3+), the remaining 169 cases were HER2 IHC negative (71.31%). Estrogen receptor status was positive about 126 cases (53.16%) while Progesterone receptor was positive in 120 cases (50.63%). The expression of proliferation marker Ki-67 differed significantly from the subtypes (p\<0.001). There were 181 cases (76.37%) with high expression of Ki-67 (≥14%), while its low expression (\<14%) was detected in 56 cases (23.63%) ([Figure 2](#F2){ref-type="fig"}). The molecular classification of breast cancer cases were statistically significant difference. Statistically significant difference was observed in the molecular classification of breast cancer cases. The majority of patients were classified as Luminal B HER2-negative (32.07%). Compared with luminal A cases, triple negative and *HER2*-overexpression were more likely to be poorly differentiated at diagnosis. On the basis of histological examination, Luminal A showed the percentage of cases with low expression of Ki-67 was 18.57% while *HER2*-overexpression and triple negative were 16.88% and 21.52%, respectively.

*Correlation of HER2 protein overexpression with clinicopathological features*

Correlation of HER2 protein overexpression with clinicopathological features was showed in [Table 3](#T3){ref-type="table"} and Supplementary Figure 3.*HER2* overexpression was significantly associated with cell proliferation index. There were no statistically significant associations between *HER2* overexpression and tumor size, histological grade, stage, lymph node metastases, Nottingham prognostic index. However, there was a trend toward increasing *HER2* overexpression in tumor having larger size, higher grade, higher stage and high Nottingham prognostic index (Supplementary Figure 3).

*Correlation of HER2 gene amplification with clinicopathological features*

Correlation of *HER2* gene amplification detected by DISH with clinicopathological features are presented in [Table 4](#T4){ref-type="table"} and Supplementary Figure 4. In our study, statistical analysis showed a significant correlation between *HER2* gene amplification and proliferation index Ki-67 (p = 0.024). However, the *HER2* gene amplification was not significantly related to other clinicopathological features including tumor size, histological grade, lymph node metastases, breast cancer staging and Nottingham prognostic index.

###### 

Patient and Tumour Characteristics of Patients with Breast Cancer

  Characteristics                               n (%)
  --------------------------------------------- -------------
  Age (54.70 ± 12.66)                           
  \<30                                          2 (0.8)
  30-39                                         21 (8.9)
  40-49                                         64 (27)
  50-59                                         77 (32.5)
  \>60                                          73 (30.8)
  Periods                                       
  Having periods                                103 (43.5)
  Menopause                                     134 (56.5)
  Location of breast tumours                    
  Upper outer quadrant                          70 (54.69)
  Upper inner quadrant                          30 (23.44)
  Lower outer quadrant                          13 (10.16)
  Lower inner quadrant                          5 (3.91)
  Central                                       10 (7.81)
  Histological classification                   
  Invasive carcinoma of no special type (NST)   181 (77.35)
  Invasive lobular carcinoma                    24 (10.26)
  Mixed lobular carcinoma                       5 (2.14)
  Metaplastic carcinoma of no special type      9 (3.84)
  Mucinous carcinoma                            12 (5.13)
  Carcinoma with apocrine differentiation       2 (0.85)
  Carcinoma with medullary features             1 (0.43)
  Tumor size (3.37 ± 1.83 cm)                   
  ≤ 2 cm                                        63 (27.16)
  \> 2 cm                                       169 (72.84)
  Histological grade                            
  Grade I                                       22 (11.76)
  Grade II                                      111 (59.36)
  Grade III                                     54 (28.88)
  Breast cancer staging                         
  Stage I                                       22 (11.22)
  Stage IIA                                     51 (26.02)
  Stage IIB                                     65 (33.16)
  Stage IIIA                                    41 (20.92)
  Stage IIIB                                    4 (2.04)
  Stage IIIC                                    13 (6.63)
  Lymph node metastases (2.54 ± 3.85)           
  0                                             83 (42.13)
  1-3                                           68 (34.51)
  ≥ 4                                           46 (23.35)
  The Nottingham prognostic index (NPI)         
  NPI I (Excellent) Score ≤2.4                  21 (10.80)
  NPI II (Good) Score \>2.4 but ≤3.4            10 (5.10)
  NPI III (Moderate) Score \>3.4 but ≤5.4       107 (54.90)
  NPI IV (Poor) Score \>5.4                     57 (29.20)

![Immunohistochemical (IHC) and Dual Color in Situ Hybridization (DISH) Analysis of Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer. A. Immunohistochemical score 0: No staining on tumor cell membrane; B. Immunohistochemical score 1: Faintly perceptible staining on \> 10% tumor cell membrane; C. Case without HER2 amplification using DISH analysis; D. Immunohistochemical score 2: Moderate staining on \> 10% tumor cell membrane; E. Immunohistochemical score 3: Strong staining on \> 10% tumor cell membrane; F. Case with HER2 amplification using DISH analysis. Pink color refer to the reference probe of Chr. 17 centromere, while brown color are the target probe for HER2](APJCP-21-1135-g001){#F1}

###### 

Molecular Characteristics of Patients with Breast Cancer

  Characteristics                                          n (%)         95% CI            *P*
  -------------------------------------------------------- ------------- ----------------- ----------
  HER2 dual in situ hybridization (DISH)                                                   
  Non-amplified                                            69 (69.00)    (25.17 - 37.31)   \< 0.001
  Amplified                                                31 (31.00)    (22.13 - 41.03)   
  HER2 immunohistochemistry                                                                
  Negative (0, 1+)                                         169 (71.31)   (23.02 - 34.90)   \< 0.001
  Positive (2+, 3+)                                        68 (28.69)    (65.10 - 76.98)   
  ER immunohistochemistry                                                                  
  Negative                                                 111 (46.84)   (40.35 - 53.41)   0.051
  Positive                                                 126 (53.16)   (46.59 - 59.65)   
  PR immunohistochemistry                                                                  
  Negative                                                 117 (49.37)   (42.84 - 55.92)   0.698
  Positive                                                 120 (50.63)   (44.08 - 57.16)   
  Cell proliferation index                                                                 
  Low (Ki67\<14%)                                          56 (23.63)    (18.37 - 29.56)   \< 0.001
  High (Ki67≥14%)                                          181 (76.37)   (70.44 - 81.63)   
  Molecular classification                                                                 
  Luminal A (ER+ or PR+; HER2-; Ki67 low)                  44 (18.57)    (13.83 - 24.12)   \< 0.001
  Luminal B HER2-negative (ER+ or PR+; HER2-; Ki67 high)   76 (32.07)    (26.17 - 38.42)   
  Luminal B HER2-positive (ER+ or PR+; HER2+; Ki67 any)    26 (10.97)    (7.29 - 15.66)    
  HER2-overexpression (ER-; PR-; HER2+; Ki67 any)          40 (16.88)    (12.34 - 22.27)   
  Triple negative (ER-; PR-; HER2-; Ki67 any)              51 (21.52)    (16.46 - 27.30)   

###### 

Correlation between HER2 Protein Overexpression and Clinicopathological Characteristics in Breast Cancer Patients

  Characteristics               HER2 IHC     *p*         
  ----------------------------- ------------ ----------- -------
  Tumor size                                             
  ≤ 2 cm                        47 (20.3)    16 (6.9)    0.587
  \> 2 cm                       120 (51.7)   49 (21.1)   
  Histological grade                                     
  Grade I                       16 (8.6)     6 (3.2)     0.282
  Grade II                      81 (43.3)    30 (16)     
  Grade III                     33 (17.6)    21 (11.2)   
  Breast cancer staging                                  
  Stage I                       17 (8.7)     5 (2.6)     0.272
  Stage II                      84 (42.9)    32 (16.3)   
  Stage III                     36 (18.4)    22 (11.2)   
  Lymph node metastases                                  
  0                             61 (31.0)    22 (11.2)   
  1-3                           48 (24.4)    20 (10.2)   0.459
  ≥ 4                           29 (14.7)    17 (8.6)    
  Cell proliferation index                               
  Low                           49 (20.7)    7 (3.0)     0.002
  High                          120 (50.6)   61 (25.7)   
  Nottingham prognostic index                            
  NPI I                         16 (8.2)     5 (2.6)     0.77
  NPI II                        7 (3.6)      3 (1.5)     
  NPI III                       76 (39.0)    31 (15.9)   
  NPI IV                        37 (19.0)    20 (10.3)   

![Immunohistochemical Characteristics of ER, PR, HER2 and Ki-67 Markers in the Tumor Sample from Breast Cancer. A. Estrogen receptor negative; B. Estrogen receptor positive; C. Progesterone receptor negative; D. Progesterone receptor positive; E. Low expression of Ki-67 (≥14%) ; F. High expression of Ki-67 (≥14%)](APJCP-21-1135-g002){#F2}

###### 

Correlation between HER2 Gene Amplification and Clinicopathological Characteristics in Breast Cancer Patients

  Characteristics               HER2 DISH   *P*         
  ----------------------------- ----------- ----------- -------
  Tumor size                                            
  ≤ 2 cm                        13 (13.0)   11 (11.0)   0.071
  \> 2 cm                       56 (56.0)   20 (20.0)   
  Histological grade                                    
  Grade I                       7 (8.6)     2 (2.5)     0.248
  Grade II                      38 (46.9)   15 (18.5)   
  Grade III                     10 (12.3)   9 (11.1)    
  Breast cancer staging                                 
  Stage I                       7 (7.1)     4 (4.0)     0.929
  Stage II                      43 (43.4)   19 (19.2)   
  Stage III                     18 (18.2)   8 (8.1)     
  Lymph node metastases                                 
  0                             29 (29.0)   11 (11.0)   0.766
  1-3                           26 (26.0)   12 (12.0)   
  ≥ 4                           14 (14.0)   8 (8.0)     
  Cell proliferation index                              
  Low                           32 (32.0)   7 (7.0)     0.024
  Hight                         37 (37.0)   24 (24.0)   
  Nottingham prognostic index                           
  NPI I                         7 (7.1)     4 (4.0)     0.917
  NPI II                        1 (1.0)     1 (1.0)     
  NPI III                       42 (42.4)   18 (18.2)   
  NPI IV                        18 (18.2)   8 (8.1)     

Discussion
==========

In the case of breast cancer, HER2 is an important prognostic factor for both clinicians and patients, and it is confirmed to be a factor related to poor prognosis (Kaptain et al., 2001). With the present study we want to determine the first correlation between *HER2* expression and clinical characteristics of breast cancer in Central Vietnam patients.

HER2 amplified or overexpressed in approximate 15 - 20% of breast cancer and associated with aggressive clinical feature if absence therapy (Figueroa-Magalhaes et al., 2014; Krishnamurti and Silverman, 2014). *HER2*gene amplification and protein over-expression are important not only as a prognostic factor but also as a predictive clinical response to anti-HER2 therapeutic (Parkes et al., 2010; Schneeweiss et al. 2014). Moreover, overall survival in patients treating with HER2-targeted therapy was higher than patients without treatment. (Mendes et al., 2015).

Determination of*HER2* gene status in breast cancer specimens has been performed at the *HER2* gene copies level using Polymerase chain reaction, Southern blotting, Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) or Dual-colour chromogenic in situ hybridization (Dual-ISH or DISH) (Furrer et al., 2015). The DISH technique is an innovation of the FISH technique that allows observing and evaluating under bright-field microscope with the additional benefit that morphological features can be observed, and that possible storage slides at room temperature (Furrer et al., 2015). Therefore, DISH has indicated several advantages compared with the use of FISH. At the protein level, HER2 status was analyzed by using Western blotting, enzyme immunoassays (ELISA) or IHC technique (Furrer et al., 2015, Zaha 2014). Similar to DISH technique, IHC also had several advantages including the ability of assessment using a conventional bright-field microscope, tissue blocks and slides can be conveniently stored. However, IHC technique was affected by numerous factors such as the temperature, time of fixation, commercially available antibodies display different specificity and sensitivity (Furrer et al., 2015). Therefore, to exactly determine HER2 status in breast cancer, in situ hybridization should be performed that combined with IHC technique. Accurate assessment of HER2 status is essential for identification of breast cancer patients that may benefit from treatment with targeted HER2 therapy (Grant et al., 2015).

In recent studies, the authors have found correlation between the overexpression of*HER2* with the Nottingham grade, lymph node metastases (Aman et al., 2019; Bartlett et al., 2007). In addition, another authors indicated that gene amplification of the *HER2* oncogene was linked to the increase of tumor size, differentiation grade and TNM stage (Aman et al., 2019; Shi et al., 2019). Different data confirm previous reports that *HER2* overexpression in breast cancer is associated with ER-negative and PR-negative disease (Bartlett et al., 2007). This study revealed that the *HER2* overexpression was closely associated with cell proliferation index. The other clinicopathological features including tumor size, histological grade, stage, lymph node metastases, Nottingham prognostic index were not significant associated with amplification of*HER2* gene and *HER2* overexpression. However, the cases with*HER2* gene amplification and/or overexpression tended to be more frequently found in tumor with large tumour size, high grade, high stage and high Nottingham prognostic index.

HER2 is one of biomarkers that play an important role in breast cancer classification. Based on ER, PR, HER2, Ki-67 marker, breast cancer can be divided into 5 groups: Luminal A (ER+ or PR+; HER2-; Ki67 low), Luminal B HER2-negative (ER+ or PR+; HER2-; Ki67 high), Luminal B HER2-positive (ER+ or PR+; HER2+; Ki67 any), HER2-overexpression (ER-; PR-; HER2+; Ki67 any), Triple negative (ER-; PR-; HER2-; Ki67 any) (Onitilo et al., 2009). In addition, classification based on *HER2* expression provides enhanced and important therapeutic guidance (Iqbal and Iqbal, 2014). Patient with subtype absence *HER2* expression will have poor prognosis and not receive most benefit from chemotherapy (Knutson et al., 2016).

Previous several studies considered NPI as a clinically useful tool for stratification of patients by incorporating traditional prognostic factors tumor size, lymph node status and histological grade (Rakha et al., 2014). Combination HER2 status to NPI can be improved its predictive ability accuracy, especially in the intermediate prognostic category of NPI (Van Belle et al., 2010). In our study, *HER2* overexpression and amplification were not significant associated with Nottingham prognostic index. Nevertheless, *HER2* overexpression tended to be observed in high Nottingham prognostic index tumours.

Cell proliferation index (Ki67) is also a prognostic and predictive factor of response to chemotherapy in breast cancer (Penault-Llorca and Radosevic-Robin, 2017). In previous researches, the cases had tumors with a high proliferative activity added to*HER-2* overexpression indicated a risk of relapse approximately higher than patients with slowly proliferation (Cheang et al., 2009; Ribelles et al., 2013). In the present study, we revealed that the extent of *HER2* status expression was significant associated with cell proliferation index Ki67.

In conclusion, this study revealed that Her2 status (gene amplification and protein overexpression) in breast cancer of Vietnamese women was significantly associated with cell proliferation index Ki67 but not with other clinicopathological features including tumor size, histological grade, stage, lymph node metastases, Nottingham prognostic index. However, the cases with *HER2* gene amplification and/or overexpression tended to be more frequently found in tumor with large tumor size, high grade, high stage and high Nottingham prognostic index.
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